Sex Differences for Regional Lewy Body Pathology in Pathologically-Defined Lewy Body Dementia
Objective: To investigate sex differences for regional Lewy body (LB) pathology burden, and regional LB pathology association with clinical diagnosis across people with a high…Longitudinal Gait Speed Analysis at Prodromal and Early Stage of Parkinson’s Disease
Objective: We aimed at exploring gait speed (GS) as a potential biomarker of disease evolution in early stages of PD with three objectives. 1- To…Early Dementia with Lewy Bodies and Parkinson’s Disease with RBD: two faces of the same coin?
Objective: To describe clinical and imaging differences in de novo PD with and without REM sleep Behaviour Disorder (dnPDRBD – de novo PD) and de…Clinical Utility of Synuclein Skin Biopsy in the Initial Diagnosis and Evaluation of Parkinsonian Disorders
Objective: To determine the clinical utility of phosphorylated alpha-synuclein (P-SYN) within skin biopsies in diagnostic and management decisions. Background: The initial diagnosis of Parkinson’s Disease…Prevalence of Non-Motor Symptoms in Patients with Parkinson Disease in a Tertiary Hospital in Santiago, Chile.
Objective: Objective:Determine the prevalence of NMS in patients with Parkinson disease attending the Hospital San Juan de Dios Neurology Clinic. Background: Background:Parkinson disease (PD) is…Clinical and epidemiological profile of Parkinson’s disease in India
Objective: To study the clinical profile and risk factors of Parkinson’s disease (PD) in India. Background: The current knowledge of clinical and epidemiological profile of…Parkinson’s Progression Markers Initiative (PPMI): Investigating Biomarker Driven PD Progression
Objective: PPMI is a longitudinal, observational study enrolling PD participants, individuals at risk for PD, and healthy controls (HCs). The study investigates clinical, imaging, genetic…The Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder (RBD)
Objective: To explore the potential for an immunologically based intervention to slow evolution of symptoms in persons with prodromal or Stage 2b (Simuni et al.…The Purely Thermodynamic Anti-prionic Mode of Action for the Treatment of Parkinson’s Disease and other Neurodegenerative Diseases
Objective: Demonstration of the anti-prionic MoA for α-synuclein in vitro, PoC in vivo, as well as ex vivo. Background: Neurodegenerative protein-misfolding diseases, like Alzheimer’s (AD)…TM9SF2 Knockdown Decreases Pathological Alpha-synuclein Aggregation In Vivo
Objective: To determine whether knockdown of transmembrane 9 super family 2 (TM9SF2) decreases the formation of alpha-synuclein inclusions and toxicity to nigral neurons in the…
- 1
- 2
- 3
- …
- 15
- Next Page »